Le Lézard
Classified in: Health, Business
Subject: LAW

Notice - BRIDGING FINANCE INC., DAVID SHARPE, NATASHA SHARPE and ANDREW MUSHORE, File No. 2022-9


TORONTO, April 23, 2024 /CNW/ - A case management hearing in the above-named matter is scheduled to be heard on April 23, 2024 at 4:30 p.m. by videoconference. 

Members of the public may observe the hearing by videoconference, by selecting the "Register to attend" link on the Tribunal's hearing schedule, at capitalmarketstribunal.ca/en/hearing-schedule.

Registrar, Governance & Tribunal Secretariat
Ontario Securities Commission

SOURCE Ontario Securities Commission


These press releases may also interest you

at 19:19
With recent news of dairy cattle in the United States testing positive for the Highly Pathogenic Avian Influenza (HPAI) and reports of fragments of HPAI detected in pasteurized milk sold in the U.S., we understand that Canadians may be concerned...

at 19:01
Butterfly Medical Ltd, an early-stage medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), is excited to announce the hiring of Patrick MacCarthy as CEO. ...

at 18:33
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...

at 18:29
Filament Health Corp. (Cboe CA: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors...

at 18:20
Starting this week, National Alliance for Hispanic Health, Ibero American Action League Inc., University of Rochester Medical Center, and Trillium Health in Rochester, NY will host the All of Us Journey, a traveling educational exhibit that brings...

at 18:00
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to...



News published on and distributed by: